ARTICLE | Finance
Direct delivery
Why Deerfield led $22.6M series A for mitochondrial disease play Chondrial
February 11, 2017 2:35 AM UTC
Preclinical proof-of-concept data for a Friedreich’s ataxia protein replacement therapy convinced Deerfield Management to lead a series A round for Chondrial Therapeutics Inc.
Chondrial raised the first undisclosed tranche of the $22.6 million round on Jan. 31. Wake Forest Innovation’s Catalyst Fund, which is managed by Pappas Capital, also participated. ...
BCIQ Company Profiles
BCIQ Target Profiles